Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives
B. Ten Haaft, Manuel Pedregal, J Prato, et al.
European Journal of Cancer (2024) Vol. 199, pp. 113564-113564
Open Access | Times Cited: 19

Showing 19 citing articles:

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
Margherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.
European Journal of Cancer (2024) Vol. 208, pp. 114199-114199
Closed Access | Times Cited: 11
Mechanism and therapeutic potential of hippo signaling pathway in type 2 diabetes and its complications
Ziqi Zhao, W.-G. Wu, Qianyi Zhang, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117817-117817
Closed Access
Advancements in Locoregional Therapies for Unresectable Intrahepatic Cholangiocarcinoma
C. O'Donnell, Umair Majeed, Michael Rutenberg, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 82-82
Open Access
Radiomic Analysis of Magnetic Resonance Imaging for Breast Cancer with TP53 Mutation: A Single Center Study
Jung Ho Park, Lyo Min Kwon, Hong Kyu Lee, et al.
Diagnostics (2025) Vol. 15, Iss. 4, pp. 428-428
Open Access
Exploring Zanidatamab’s efficacy across HER2-positive Malignancies: a narrative review
Warisha Kanwal, Kaneez Narjis, Sarah Musani, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Real-World Efficacy of Zanidatamab in Patients with Her2-Amplified Advanced Biliary Tract Cancers
Cristina Smolenschi, Jean‐Frédéric Blanc, Anna Lancry, et al.
(2025)
Closed Access
Molecular signatures of intrahepatic Cholangiocarcinoma: Role in targeted therapy selection
Tetiana Glushko, James Costello, Ranjit S. Chima, et al.
European Journal of Radiology (2025), pp. 112056-112056
Closed Access
Adenomyoma/adenomyomatosis-associated mural intracholecystic neoplasms: analysis of clinico-pathologic, imaging, and molecular features of a consecutive case series
Alessandro Vanoli, Erica Travaglino, Marco Minetto, et al.
Virchows Archiv (2025)
Open Access
Review of the mechanisms of the biliary-enteric axis in the development of cholangiocarcinoma
Tianhao Shen, Xue Yu, Cheng Zhou, et al.
World Journal of Clinical Oncology (2025) Vol. 16, Iss. 4
Closed Access
The Recent Trends of Systemic Treatments and Locoregional Therapies for Cholangiocarcinoma
Abdullah Esmail, Mohamed Badheeb, Batool Wael Alnahar, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 910-910
Open Access | Times Cited: 3
Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy
Semir Vranić, Zoran Gatalica
Biomolecules and Biomedicine (2024) Vol. 24, Iss. 4, pp. 673-675
Open Access | Times Cited: 1
Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies
Christiana Mo, Michelle Sterpi, Hyein Jeon, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2854-2854
Open Access | Times Cited: 1
Defining and Refining the Role of Adjuvant Chemoradiation for Biliary Tract Cancers After SWOG 0809
Belkacem Acidi, Hop S. Tran Cao
Annals of Surgical Oncology (2024) Vol. 31, Iss. 8, pp. 4837-4838
Closed Access
Safety of current treatments for advanced cholangiocarcinoma
Tiago Biachi de Castria, Richard D. Kim
Expert Opinion on Drug Safety (2024), pp. 1-9
Closed Access
Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A Large Real-Life Worldwide Population
Margherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.
(2024)
Closed Access
Double hit — bispecific antibodies in cancer therapy
Alicja Bogdanowicz, Kamila Wojas‐Krawczyk, Natalia Krzyżanowska, et al.
Oncology in Clinical Practice (2024)
Open Access
A prognostic model and novel risk classification system for radical gallbladder cancer surgery: A population-based study and external validation
Feng Yuan, Junjun Yang, Ankang Wang, et al.
Heliyon (2024) Vol. 10, Iss. 15, pp. e35551-e35551
Open Access
Which therapy in biliary tract cancer? Review of main concerns in diagnosis and choice of therapy in advanced setting, current standard, and new options
Ester Oneda, Serena Astore, Laura Gandolfi, et al.
Expert Opinion on Pharmacotherapy (2024)
Open Access
Antibody-Drug Conjugates and Their Potential in the Treatment of Patients with Biliary Tract Cancer
Shaun Alexander, Umair Aleem, Timothy W. Jacobs, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3345-3345
Open Access
Page 1

Scroll to top